Banned medicine (Credit-Canva)
The Union Health Ministry implemented a ban on 156 "irrational" FDC medicines, effective immediately. These medicines, including widely used antibiotics, painkillers, and multivitamins, were commonly used to treat fever, cough, and infections. The ban was imposed due to the associated health risks and lack of therapeutic justification for the ingredients in these FDCs.
FDCs or fixed-dosed combinations, also known as "cocktail drugs," are medications that combine multiple drugs in a single pill. They are designed to treat multiple symptoms or conditions simultaneously. While they offer convenience, they can pose significant risks. These risks include the possibility of overdose, adverse interactions between the drugs, and the development of antibiotic resistance. Additionally, many FDC medicines lack sufficient scientific evidence to support their safety and efficacy.
Experts have raised concerns about the use of FDC medicines. They believe that many of these combinations lack sufficient scientific evidence to support their safety and effectiveness. Additionally, the combination of multiple drugs in a single pill can increase the risk of adverse side effects and interactions with other medications.
Experts have also found that FDC medicines may not be as effective as individual drugs in treating certain conditions. It is important to note that safer and more effective alternatives are available for most of the medical conditions that FDC medicines were used to treat. One particular concern is the inclusion of antibiotics in some FDCs. Overuse of antibiotics can contribute to the development of antibiotic resistance, a major public health threat.
The use of FDC medicines can lead to adverse effects, including serious ones. Additionally, safer alternatives, tested in clinical trials, are available to treat the same medical conditions. Experts recommend prescribing drugs individually based on a patient's clinical symptoms rather than combining them in FDCs.
The ban on irrational FDC medicines by the Union Health Ministry can be seen as a positive step towards promoting rational drug use and protecting public health. The goal is to eliminate unnecessary and potentially harmful drug combinations. This is a step forward in reducing the risks associated with medication and ensure safer and more effective treatment options for patients.
Credit: Instagram
Prostate cancer is the most common cancer among men in the UK. The country records around 55,000 new prostate cancer cases and nearly 12,000 deaths every year.
Although the UK recently ruled out universal prostate cancer screening, opting instead for targeted screening of high-risk men, new cases continue to emerge every day. The latest high-profile figures diagnosed with the disease are former Liverpool winger John Barnes and comedian Bobby Davro.
Barnes revealed that he had his prostate removed following a cancer diagnosis and described the condition as a "taboo subject" for men.
"Not many people know and it’s a bit of a taboo subject because we support women with breast cancer and it’s not even an issue," he told Times Radio.
Barnes stressed that "a lot of men don’t want to admit it or want to have it done because it makes them feel less than a man."
He added: "Men have to bite the bullet and swallow their pride and admit if they have problems."
Also read: Jill Biden Opens Up About Joe Biden’s Lifelong Cancer Battle
Meanwhile, 67-year-old Bobby Davro spoke on This Morning about his diagnosis, revealing that he had experienced erectile dysfunction beforehand.
Speaking on the ITV show, Davro said: "I think one in eight men get it. I think a lot of men of color, they get more prostate cancer, so it’s got to be checked.
"So go along and have your PSA (Prostate-Specific Antigen) checked, have the old prostate examined."
Davro continued: "He [the doctor] said: 'It’s a bit swollen, I think you should go and have a PSA test.' And it was 24, which wasn’t good at all."
"Not really. The only thing I had was erectile dysfunction. It wasn’t nice. I tried taking the blue pills. I realised something wasn’t quite right," he said about symptom before diagnosis.
Many other high-profile figures have been diagnosed with prostate cancer, including former UK Prime Minister David Cameron, BBC radio host Bob Harris, and six-time Olympic gold medalist Chris Hoy.
Despite the high burden of disease, the UK currently has no national prostate cancer screening program because of concerns over the accuracy of PSA tests. However, there has been growing pressure in recent years to introduce routine screening.
Read More: Benjamin Netanyahu Undergoes Treatment For Early-stage Prostate Cancer
After reviewing the latest evidence, the National Screening Committee (NSC) recommended against broad population-wide screening for prostate cancer.
The committee said the harms of screening outweigh the benefits for most groups. The final guidance states that routine screening should not be offered to:
Instead, the NSC recommends:
Symptoms To Watch For
The prostate is a small walnut-shaped gland in men that produces seminal fluid, which nourishes and transports sperm. Prostate cancer develops when abnormal cells begin growing in the gland.
Common symptoms include:
Credit: iStock
Alkem Laboratories today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths, with prices starting at Rs 350.
The company, in a statement, said it is the first in India to introduce semaglutide in a single-shot pre-filled syringe format for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
The ready-to-use format will expand treatment options for patients while lowering entry barriers through affordable pricing.
“Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced,” said Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories.
“In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy,” he added.
Alkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes.
Also read: India To Tighten Regulation For Semaglutide, Other GLP-1 Drugs
The launch follows Alkem’s introduction of semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market in March 2026. The company has also secured regulatory approval for semaglutide vials, which it plans to launch soon.
Meanwhile, domestic peers such as Torrent Pharma and Dr Reddy’s have also introduced non-infringing tablets, with Lupin, Sun Pharma and several others expected to follow suit.
Semaglutide: Risks Vs Benefits
In people with type 2 diabetes, Harvard Health noted that the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.
These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.
Notably, semaglutide is not just a glucose-lowering drug, it improves weight and has proven cardiovascular, liver, and renal benefits.
Read More: Pairing Ozempic With Exercise Is Beneficial For Your Muscles, Study Finds
Wider availability could therefore help reduce long-term complications such as heart disease and kidney failure. If used appropriately, this could indeed be a major step forward in total metabolic care, the experts said.
“The increasing affordability of GLP-1 receptor agonists is a double-edged development. On one hand, it significantly improves access for patients with obesity, type 2 diabetes, and high cardiovascular risk, conditions that are highly prevalent in India. These drugs have demonstrated meaningful benefits in weight reduction, glycemic control, and even cardiovascular risk reduction, which could translate into long-term public health gains,” Dr Vivek Bindal, Senior Director & Head, Bariatric and Robotic Surgery, at Max Healthcare, told HealthandMe.
Credit: iStock
Western Australia is seeing a steady rise in mpox infections, with seven cases reported during the past week, according to the Department of Health.
In a statement, the department said that 22 mpox cases have been reported in Western Australia so far in 2026. The figure marks a significant increase compared with 2025, when 27 cases were recorded throughout the entire year, and 2024, which saw 23 cases.
Health officials have advised the public to remain alert for symptoms of the disease. Public health investigations and contact tracing are also underway to prevent further transmission.
Nineteen of the cases were acquired locally, while three were linked to overseas travel. Two of the cases reported this year were in cisgender women, a first for Western Australia. Another two cases were reported in heterosexual men, the officials said.
Dr. Paul Armstrong, Director of Communicable Disease Control, said the department was working closely with affected individuals and their contacts to help prevent further spread of the virus.
“Mpox is a viral infection that typically causes mild illness, including fever, headache, muscle aches, swollen lymph nodes, or fatigue, followed by a skin rash or lesions,” Dr Armstrong said.
“It does not spread easily between people and is mainly transmitted through very close or intimate contact with an infected person.
“While anyone can contract mpox, recent cases in Australia and internationally have occurred more commonly among sexually active gay, bisexual, and other men who have sex with men,” the expert said.
Dr Armstrong encouraged eligible people in Western Australia to consider vaccination, particularly before travelling to countries experiencing mpox transmission.
“The mpox vaccine is available through sexual health clinics and participating GPs for people at higher risk of exposure,” he said.
“Two doses are recommended for optimal protection, and vaccination can reduce the risk of infection and severe disease.”
Anyone concerned they may have been exposed to mpox, or experiencing symptoms consistent with the infection, should call ahead before attending a healthcare facility so appropriate precautions can be arranged.
Mpox is a viral disease caused by the monkeypox virus, which belongs to the same family of viruses as smallpox.
The virus spreads through close physical contact with an infected person, contaminated materials, or infected animals.
The illness generally lasts between two and four weeks and resolves on its own. However, severe disease can occur, particularly in children, pregnant women, and people with weakened immune systems.
Complications may include secondary infections, respiratory problems, and, in rare cases, death.
Also read: India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6
Vaccination: Vaccines originally developed for smallpox can help protect against mpox. Health authorities recommend vaccination for people at higher risk of exposure.
Good Hygiene: Regular handwashing, avoiding close contact with infected individuals and contaminated materials, and following public health guidance can reduce the risk of infection.
Early Detection And Monitoring: People who develop symptoms or believe they may have been exposed should seek medical advice promptly. Laboratory testing, including RT-PCR, is available to confirm infection and support timely treatment and contact tracing.
© 2024 Bennett, Coleman & Company Limited